Home / USA / U.S. Courts and Public Health
U.S. COURTS · PUBLIC HEALTH · ALASKAAlaska Supreme Court Revives Opioid Lawsuit Against Pharmacy Chains
Alaska's highest court has allowed the state's public nuisance claim against several pharmacy operators to move forward. The ruling revives part of a case tied to opioid dispensing practices, but it does not determine whether any company is liable.
ANCHORAGE, Alaska, November 7, 2026: The Alaska Supreme Court has revived the state's public nuisance lawsuit against companies operating Safeway and Fred Meyer pharmacies, sending that part of the case back to the trial court. The justices ruled on November 6 that the state's allegations, if proven, could describe an unreasonable interference with public health and safety.
What the Alaska Supreme Court decided
The opinion, State of Alaska v. Albertsons Companies, Inc., reverses the dismissal of the state's public nuisance claim. The defendants named in the case include Albertsons Companies, Albertsons Companies LLC, Safeway, Carr-Gottstein Foods, The Kroger Co. and Fred Meyer.
The court did not decide that the pharmacies caused the opioid crisis or that they violated the law. The case was at an early stage, when judges review whether the complaint describes a legally recognizable claim. For that purpose, the court had to treat the state's factual allegations as true. The companies will have an opportunity to contest those allegations as the case returns to the Anchorage Superior Court.
The ruling also left most of the state's claims under Alaska's Unfair Trade Practices and Consumer Protection Act dismissed. One narrower theory survived: the state's allegation that the companies publicly promoted their compliance and anti-diversion efforts in a way that created a misleading impression about whether they were meeting their obligations.
What Alaska alleges about prescription monitoring
Alaska filed the lawsuit in 2022. The state alleges that the pharmacy operators failed to adequately monitor, investigate and report suspicious opioid prescriptions, despite legal duties designed to prevent controlled substances from being diverted into illegal channels.
Those claims involve the systems pharmacies use to identify unusual orders, the steps taken when a prescription raises a red flag, and whether staff follow through before dispensing medication. The state argues that failures at the retail pharmacy level allowed more prescription opioids to enter circulation and contributed to wider harms associated with addiction and overdose.
These are allegations in a civil complaint, not findings made after a trial. The Supreme Court's decision allows the public nuisance claim to proceed because the state described harm to collective interests such as public health and safety. It did not resolve questions about causation, the conduct of individual pharmacists or the companies' defenses.
Why the public nuisance claim matters
The companies argued that selling a lawful product should not, by itself, create a public nuisance claim. The Alaska Supreme Court declined to adopt a categorical rule that would prevent such claims whenever a case involves the sale of a product.
The justices focused on the state's allegation that pharmacies have specific legal responsibilities when dispensing controlled substances. Unlike an ordinary retailer, a pharmacy is subject to detailed rules for handling prescription opioids, monitoring suspicious orders and reporting certain problems. The court concluded that the state's allegations about those duties were enough to let the nuisance claim continue.
The distinction is important. The ruling does not mean every business that sells a product can be sued as a public nuisance. It means the particular allegations about regulated pharmacy conduct in this case were sufficient to survive dismissal under Alaska law.
What remedies could be considered later
Alaska has sought court orders aimed at stopping the practices it says contributed to the problem and reducing the harm already caused. The state's requested remedies have included measures such as supporting addiction treatment and making naloxone, a medication used to reverse opioid overdoses, more widely available.
Those requests are not an award of money or an order currently imposed on the companies. Any remedy would depend on later proceedings, evidence and the legal standards that apply. The defendants can challenge the state's allegations and argue that the requested relief is not justified.
How the case fits into wider opioid litigation
States and local governments have pursued opioid-related cases against manufacturers, distributors and pharmacy operators. The legal theories and outcomes differ. Some cases have ended in settlements, while others have focused on whether a particular defendant had a legal duty that was breached and whether that conduct caused a public harm.
Alaska's case is notable because the Supreme Court addressed the role of retail pharmacies as the final point in the distribution chain. The court's opinion also shows that the state's consumer-protection claims and its public nuisance claim are not identical: most of the former were dismissed, while the latter can proceed.
What happens next
The case returns to the Anchorage Superior Court for further proceedings. The next phase can involve evidence, motions and arguments about whether the state can prove its claims. The Supreme Court's ruling sets the legal framework for the claim to continue, but it does not predict how the trial court will ultimately rule.
For patients and families affected by opioid addiction, the decision is one step in a legal process, not an immediate change to pharmacy services or access to treatment. For the companies, it means defending a claim that had previously been dismissed. The central questions of responsibility and remedy remain unresolved.
- Alaska Supreme Court opinion, State v. Albertsons Companies, Inc., Opinion No. 7836 (Nov. 6, 2026)
- Reuters, Alaska high court revives opioid lawsuit against pharmacy operators (Nov. 6, 2026)
Editorial note: The Supreme Court reviewed whether the complaint could proceed at the dismissal stage. It did not make a finding that the companies caused the opioid crisis or violated the law.
Related coverage: Latest U.S. news · Politics and government · Technology coverage